Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer

The heterogeneity of an individual patient’s tumor has been linked to treatment resistance, but quantitative biomarkers to rapidly and reproducibly evaluate heterogeneity in a clinical setting are currently lacking. Using established tools available in a CAP-accredited and CLIA-certified clinical la...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Res
Autores principales: Scher, Howard I., Graf, Ryon P., Schreiber, Nicole A., McLaughlin, Brigit, Jendrisak, Adam, Wang, Yipeng, Lee, Jerry, Greene, Stephanie, Krupa, Rachel, Lu, David, Bamford, Pascal, Louw, Jessica E., Dugan, Lyndsey, Vargas, Hebert A., Fleisher, Martin, Landers, Mark, Heller, Glenn, Dittamore, Ryan
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5666339/
https://ncbi.nlm.nih.gov/pubmed/28819021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-1353
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares